MedPath

Enhancing Communication and HIV Outcomes

Phase 3
Completed
Conditions
HIV Infections
Registration Number
NCT00675610
Lead Sponsor
Johns Hopkins University
Brief Summary

The goal of this research is to improve communication between the patients with HIV and their health care providers. The overall purpose of doing so is to reduce disparities in medication self-efficacy, adherence to therapy, and HIV viral load suppression. The investigators will conduct a randomized controlled trial to test the effectiveness of a combined provider and patient communication intervention conducted at two separate visits compared to usual care in improving the quality of patient-provider communication, patients' medication self-efficacy, patient adherence to therapy, and HIV RNA suppression.

Detailed Description

The goal of this research is to improve communication between the patients with HIV and their health care providers. The overall purpose of doing so is to reduce disparities in medication self-efficacy, adherence to therapy, and HIV viral load suppression. We will conduct a randomized controlled trial to test the effectiveness of a combined provider and patient communication intervention conducted at two separate visits compared to usual care in improving the quality of patient-provider communication, patients' medication self-efficacy, patient adherence to therapy, and HIV RNA suppression. The following primary and secondary hypotheses will be addressed.

Primary Hypothesis.

1) There will be more and higher quality patient-provider communication about antiretroviral medication adherence in the intervention compared to control arm at both visit 1 (V1) and visit 2 (V2).

Secondary Hypotheses

1. Higher quality patient-provider communication in the intervention arm will be associated with

* higher patient ratings of communication (overall, HIV-specific, adherence-specific, and interpersonal style of provider) at V1 and V2;

* increased patient preference for a shared decision-making role at V1 and V2;

* more positive health beliefs at V1 and V2;

* higher patient medication self-efficacy at V1 and V2;

* better adherence to antiretroviral medication (assessed by 3-day recall) at V2; and

* a greater percentage of patients with HIV-1 RNA suppression at V2.

2. The intervention will reduce disparities in medication self-efficacy, adherence, and HIV-1 RNA suppression.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
186
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
patient-provider communication1 day- 3 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Wayne State University

🇺🇸

Detroit, Michigan, United States

Saint Lukes-Roosevelt

🇺🇸

New York, New York, United States

Oregon Health Science University

🇺🇸

Portland, Oregon, United States

Wayne State University
🇺🇸Detroit, Michigan, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.